IP Library Granted Patent US 8,598,186
Granted Patent B2
US 8,598,186 · App. 13/869,520 · Granted Dec 3, 2013

CDK inhibitors

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,598,186
App. No.
13/869,520
Granted
Dec 3, 2013
Kind
B2
Abstract

Compounds of formulae I, II or III, and pharmaceutically acceptable salts thereof, are useful as CDK inhibitors.

Claims (32)

1. A compound of the formula:

or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition comprising an effective amount of the compound of claim 1 in a pharmaceutically acceptable carrier.

3. A compound of the formula:

or a pharmaceutically acceptable salt thereof.

4. A pharmaceutical composition comprising an effective amount of the compound of claim 3 in a pharmaceutically acceptable carrier.

5. A compound of the structure:

wherein R 2 is -(alkylene) m -heterocyclo or -(alkylene) m -heteroaryl,

R is hydrogen, and

X is independently CH or N.

6. The compound of claim 5 , wherein R 2 is -(alkylene) m -heterocyclo.

7. The compound of claim 5 , wherein m is 0.

8. The compound of claim 6 , wherein m is 0.

9. The compound of claim 5 , wherein m is 1.

10. The compound of claim 6 , wherein m is 1.

11. The compound of claim 5 , wherein the heterocyclo is not substituted.

12. The compound of claim 6 , wherein the heterocyclo is not substituted.

13. The compound of claim 5 , wherein R 2 is

14. A pharmaceutical composition comprising an effective amount of the compound of claim 5 in a pharmaceutically acceptable carrier.

15. A compound of the structure:

wherein R 2 is -(alkylene) m -heterocyclo or -(alkylene) m -heteroaryl,

R is hydrogen, and

X is independently CH or N.

16. The compound of claim 15 , wherein R 2 is -(alkylene) m -heterocyclo.

17. The compound of claim 15 , wherein m is 0.

18. The compound of claim 16 , wherein m is 0.

19. The compound of claim 15 , wherein m is 1.

20. The compound of claim 16 , wherein m is 1.

21. The compound of claim 15 , wherein the heterocyclo is not substituted.

22. The compound of claim 16 , wherein the heterocyclo is not substituted.

23. The compound of claim 15 , wherein R 2 is

24. A pharmaceutical composition comprising an effective amount of the compound of claim 15 in a pharmaceutically acceptable carrier.

Assignments (9)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 23, 2025
From: PHARMACOSMOS THERAPEUTICS, INC.
To: PHARMACOSMOS A/S
Reel/Frame 071018/0280 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 23, 2025
From: PHARMACOSMOS A/S
To: PHARMACOSMOS HOLDING A/S
Reel/Frame 071018/0238 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 22, 2024
From: G1 THERAPEUTICS, INC.
To: PHARMACOSMOS A/S
Reel/Frame 069371/0820 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 22, 2024
From: PHARMACOSMOS A/S
To: PHARMACOSMOS HOLDING A/S
Reel/Frame 069371/0832 →
RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Sep 19, 2024
From: HERCULES CAPITAL, INC., AS COLLATERAL AGENT
To: G1 THERAPEUTICS, INC.
Reel/Frame 068996/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 29, 2021
From: TAVARES, FRANCIS X.
To: G1 THERAPEUTICS, INC.
Reel/Frame 055746/0368 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 25, 2021
From: STRUM, JAY C.
To: G1 THERAPEUTICS, INC.
Reel/Frame 055725/0743 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded May 29, 2020
From: G1 THERAPEUTICS, INC.
To: HERCULES CAPITAL, INC., AS COLLATERAL AGENT
Reel/Frame 052795/0074 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 9, 2016
From: STRUM, JAY C; TAVARES, FRANCIS X
To: G1 THERAPEUTICS, INC.
Reel/Frame 038521/0595 →